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Olivia Oxlade1, Amy Piatek3, Cheri Vincent3 and Dick Menzies1,2*Abstract
Background: Tuberculosis (TB) programs must invest in a variety of TB specific activities in order to reach ambitious
global targets. Uncertainty exists surrounding the potential impact of each of these activities. The objective of our
study was to model different interventions and quantify their impact on epidemiologic outcomes and costs from
the health system perspective.
Methods: Decision analysis was used to define the TB patient trajectory within the health system of three different
countries. We considered up to seven different interventions that could affect either the natural history of TB, or
patient trajectories within the health system. The expected impact of interventions were derived from published
studies where possible. Epidemiologic outcomes and associated health system costs were projected for each
scenario.
Results: With no specific intervention, TB related death rates are high and less than 10% of the population starts on
correct treatment. Interventions that either prevent cases or affect all patients with TB disease early in their
trajectory are expected to have the biggest impact, regardless of underlying epidemiologic characteristics of the
setting. In settings with a private sector, improving diagnosis and appropriate treatment across all sectors is
expected to have a major impact on outcomes.
Conclusion: In all settings, the greatest benefit will come from early diagnosis of all forms of TB. Once this has
been achieved more specific interventions, such as those targeting HIV, drug resistance or the private sector can be
integrated to increase impact.
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Beginning in the mid-1980s, tuberculosis (TB) inci-
dence dramatically increased globally, mostly attrib-
uted to urbanization in low and middle income countries
(LMIC) and the HIV/AIDS epidemic. The emergence of
multi drug-resistant TB (MDR-TB) has further contrib-
uted to the challenges of TB diagnosis and treatment. In
response to the TB crisis, the World Health Organization
(WHO) declared TB a global emergency in 1993. The
Stop TB Partnership and the Global TB Drug Facility
(GDF) [1,2] were created to help provide more support to* Correspondence: dick.menzies@mcgill.ca
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unless otherwise stated.countries, especially to National TB Programs (NTP), and
by the late 1990s the United States Government started to
provide funding to support NTP activities.
In 2006, WHO and the Stop TB Partnership launched an
ambitious global plan to reach the Millennium Development
Goal (MDG) targets of a 50% reduction in TB prevalence
and mortality [3]. The Stop TB Strategy provided the
operational plan to reach these targets and included a
comprehensive approach to improve TB case detection
and treatment outcomes [1]. Increases in funding by
external donor agencies and some national govern-
ments have led to the implementation of the global
plan and progress toward the MDGs [4].
As a result of these efforts, TB prevalence and mortality
have declined. However, in 2013 there were 9.0 millionThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[3]. A new post-2015 plan has been developed by global
partners calling for increased investment in both evidence-
based and innovative strategies to achieve 90% reduction
in cases and zero TB deaths [5,6]. Given the uncertainty on
how to effectively and efficiently achieve these ambitious
objectives, we have modeled the potential impact of differ-
ent TB interventions on long term epidemiologic out-
comes and health system costs.
Methods
General approach to modeling
We used decision analysis to compare the impact on ep-
idemiologic outcomes, and health system costs of differ-
ent interventions to strengthen TB programs in LMICs
that could affect either the natural history or patient tra-
jectories of TB disease. Pathogenetic and epidemiologic
inputs, as well as the impact of interventions, were de-
rived from the published literature. The model predicted
the number of new primary and associated secondary
TB cases, TB mortality, and TB related national health
system costs over 20 years (2001-2020).
Population
Three countries (Indonesia, Kazakhstan, and Mozambique)
with different initial incidence of active disease, prevalence
of drug resistance, HIV co-infection and health provider
landscape were considered. Indonesia was considered rep-
resentative of high TB burden, but low drug resistance and
low HIV burden, with a private sector. Kazakhstan was
considered representative of high TB burden, with high
drug resistance, but low HIV burden and no private sector
and Mozambique was considered high TB burden, with
low drug resistance, and high HIV burden and with no pri-
vate sector.
For each country-specific epidemiologic data relating
to TB incidence, treatment outcomes, drug resistance
and HIV co-infection were taken from published sources
[7-9]. Drug resistance was categorized as multi drug re-
sistant (MDR-TB) - which included any form of Rifampin
resistance or drug sensitive (DS-TB). DS-TB included all
cases that were not classified as MDR-TB, including those
that were mono- and poly-drug resistant.
Overview of decision analysis model
A decision analysis model was constructed based on a
conceptual framework developed to represent the nat-
ural history of TB and opportunities for intervention
(see Additional file 1: Figure S1 for more detail). The
population cohort was initially divided into those with
and without TB infection. The population was then fur-
ther stratified by HIV infection status as well as drug
resistance.Each year, those who were uninfected with TB could
stay uninfected or acquire infection. Those with TB in-
fection could remain without disease (with latent infec-
tion), or develop active disease in each year; this rate
was higher in the first two years after infection. As sum-
marized in Additional file 1: Figure S2 in the supple-
ment, individuals with active TB could then begin
seeking care. Individuals could either seek care without
any delay, or after a delay. Depending on the setting, pa-
tients could seek care at different types of health facil-
ities (in up to 3 sectors –public, informal (such as
natural healers), or private). In each sector a correct or
an incorrect diagnostic test could be ordered. If an in-
correct test was ordered an individual would not be di-
agnosed, and would remain untreated. If a correct
diagnostic test was ordered, this test could be ordered
immediately, or with a delay. Some patients will not con-
tinue through the process to receive a diagnostic result.
If diagnosed, the treatment prescribed could be correct
(i.e. an NTP- or WHO-recommended regimen), or in-
correct. If incorrect it was assumed the therapy was inef-
fective and cure rates were lower than those specified
for recommended therapy. TB treatment could be initi-
ated immediately, or after a delay. For those with MDR-
TB disease, patients could receive a drug susceptibility
test (DST) and be prescribed appropriate treatment, or
not receive a DST and be given treatment for DS-TB
(considered ineffective). Of those who started on correct
therapy some completed treatment and were cured,
others lost to follow-up, were not cured, relapsed or
died. Active cases that received no treatment or inad-
equate treatment were considered to continue to trans-
mit M. tuberculosis to the community until they either
cured spontaneously or died from TB. This contributed
to the number of secondary active cases generated dur-
ing the simulation. Cases that incurred any delay were
considered to continue to transmit the bacilli and could
die during the period of delay. Specific probabilities of
all of these events occurring are described below.
Pre-intervention inputs
Epidemiologic inputs
Epidemiologic inputs (initial annual risk of TB infection,
HIV and drug resistance rates) varied by country. Patho-
genetic inputs and outcomes for undiagnosed/untreated
cases varied by HIV status. Input values, taken from
published studies, are summarized in the supplemental
appendix (Additional file 1: Table S1).
Diagnostic and treatment related inputs
Pre-intervention diagnostic variables are summarized in
Additional file 1: Table S2 and S3 in the supplemental
appendix. Most inputs varied by sector (where relevant),
but not by country, and were identified through an
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effect of programme interventions on TB diagnostic and
treatment outcomes. Since published estimates of pa-
tient, diagnostic, and treatment delays are generally aver-
age times in days or months, these average delays were
converted into the probability of a one year delay. For
example, an average delay of 30 days was considered
equivalent to a one year delay for 8% of those with active
TB seeking care, and no delay for the remaining 92%.
TB treatment outcomes varied by country, type of
underlying drug resistance, HIV status, and if DST was
performed (Additional file 1: Table S3 in the supplemen-
tal appendix). In the pre-intervention scenario, HIV in-
fected individuals were assumed to have no access to
anti-retroviral therapy (ART).
Health system costs
All costs are summarized in Additional file 1: Table S4
in the supplemental appendix. Per item health system
costs included those associated with TB diagnosis and
treatment. TB treatment costs included drug costs, costs
associated with DOT visits, and monthly medical follow
up costs. Treatment costs were calculated separately for
DS cases and MDR cases to reflect the higher drug costs
and much longer duration of follow up. For DS or MDR
cases that were lost to follow up, 50% of the full treat-
ment cost was attributed. Medical visit costs (ie. medical
follow up and treatment visit costs) varied by country
[10,11] and were adjusted using World Bank data [12].
Diagnostic test, DST and drug costs were priced using
WHO CHOICE data [13] and other international sup-
pliers [2]. Costs associated with the implementation of
the interventions were not included, because none of the
published studies providing information on the impact
of interventions considered provided corresponding cost
estimates. All costs are in 2010 US Dollars.
Interventions
Using the conceptual framework described above (see
Additional file 1: Figure S1 for more detail), TB related
interventions were matched to the stages of a TB pa-
tient’s natural history and trajectory through the health
system. For example, investment in laboratory strength-
ening was considered an intervention that would affect
diagnosis during the “diseased” stage of the framework.
Interventions were considered if they had been sup-
ported by external funding agencies in the past and were
prioritized during periods of NTP strengthening or ex-
pansion since 2000. Interventions were grouped into one
of seven categories: 1) Community education, 2) Expan-
sion of TB diagnostic network (DOTS expansion for
Diagnosis), 3) Education and supervision of health care
workers about correct treatment regimens (DOTS expan-
sion for treatment), 4) Other DOTS expansion interventionsnot specifically related to diagnosis or treatment (Non Spe-
cific DOTS expansion- NTP strengthening), 5) Private
sector interventions, 6) Expanded access to DST and
reduced loss to follow up during treatment – for MDR
(MDR-TB related Interventions), 7) Expanded access
to ART for HIV co-infection (HIV/ART Therapy Pro-
grams). Each category of intervention could involve
several potential specific activities. For example, for
Intervention 3 (DOTS expansion for treatment) activ-
ities could include training of doctors, nurses and
pharmacists on TB guidelines, monitoring and man-
agement of supplies of high quality drugs or transla-
tion and printing of training materials for community
based DOTS. However, we assumed that these differ-
ent activities would result in similar impacts in the
model, and did not model the impact of these specific
activities separately.
Key model parameters affected by intervention
(Table 1) For each intervention one or more model pa-
rameters were assumed to change over time following
the intervention. For example for Intervention 2 (DOTS
expansion for diagnosis) three different model probabil-
ities were assumed to change (probability of incorrect
diagnostic test ordered, diagnostic delay and loss to fol-
low up during diagnostic work up). The interventions,
together with corresponding probabilities assumed to
change with each intervention, are summarized in Table 1.
Many parameters relating to the effect of types of inter-
ventions were obtained through a systematic review of
published studies of the impact of TB control interven-
tions on TB outcomes and indicators, and were assumed
to be the same in all 3 countries. A few pre-intervention
parameters varied by country (e.g., frequency of loss to fol-
low up), but most were assumed to be the same in all
three countries.
Projected outcomes
Projected outcomes, over a 20 year time frame, included:
primary active cases, secondary active cases generated from
primary cases, TB related deaths (during diagnosis or treat-
ment phases), and health system costs (from the perspec-
tive of the national health system in the 3 countries).
To better understand the contribution of changing
specific model parameters associated with general inter-
ventions, projected outcomes were presented separately
for each model parameter assumed to be influenced by
the intervention. Discounting was not used because a
cost effectiveness analysis was not performed, and the
primary predicted outcomes were epidemiologic.
Sensitivity analysis
The individual effect of each key model parameter de-
scribed in Table 1 was investigated in sensitivity analysis,
Table 1 Pre and post intervention values for specific model parameters










Notes and Reference for post intervention
Community Education Patient delay (probability
of seeking care with a
1 year delay)
41 · 79 days = 0 · 11
probability of a 1 year
delay
[14-17] 21 days = 0 · 06
probability of a 1
year delay
Assume 50% reduction in delay days
DOTS expansion for diagnosis Incorrect diagnostic test
ordered by heath professional
0 · 603 [18] 0 · 351 [19]
Diagnostic delay (probability
of incurring a 1 year delay)
29 · 49 days = 0 · 081
probability of a 1 year
delay
[14-17] 1 · 83 days = 0 · 005
probability of a 1 year
delay
Used pre-intervention data and ratio of delay
days "pre" and "post" intervention from [20]
to obtain post-intervention estimate of delay days
Loss to follow up during
diagnostic work-up
0 · 254 [21-24] (Assume that loss to
follow up is the same for
regardless of provider)
0 · 140 Used pre-intervention data and ratio of outcomes
"pre" and "post" intervention from [19] to obtain
post-intervention estimated of loss to follow up
DOTS Expansion for Treatment Incorrect treatment 0 · 791 [25] 0 · 129 [25] Scenario assumed that incorrect treatment
was given regardless of DST availability
Non specific DOTS Expansion
(NTP Strengthening)
Initial access- inaccessible
provider (ie · probability
that patient seeks care with
alternative provider that
is inaccessible to interventions)
0 · 055 [14,26-31] 0 · 025 Intervention assumed to have same impact as in
private sector
Private Sector interventions Incorrect diagnostic test
ordered by private provider
0 · 622 [18] 0 · 362 [19]
Diagnostic delay (private
sector only)
0 · 11 [14-17] (# days pre-intervention) 0 · 007 Used pre-intervention data and ratio of delay days
"pre" and "post" intervention from [20] to obtain
post-intervention estimate of delay days and then
used ratio of outcomes in public vs private sector
from [14] [27,32,33] to extrapolate estimate for
public system to private system
Loss to follow up during
diagnosis (private sector only)
0 · 254 [21-24] 0 · 140 Assumed to be same as in public sector (a 45%
reduction). Used pre-intervention data and ratio of
outcomes "pre" and "post" intervention from [19]
to obtain post-intervention estimated of drop out
Incorrect treatment by private
provider
0 · 771 [34] 0 · 126 Used pre-intervention data and ratio of outcomes
"pre" and "post" intervention from [25] to obtain
post-intervention estimate of incorrect treatment
HIV/ ART therapy programmes TB Death rate in HIV/TB
co-infected
0 · 12 [35] 0 · 10 [35] [36,37] (see table S5 in Supplement appendix
for more detail)
TB Relapse rate HIV/TB
co-infected
0 · 16 [36] 0 · 01 [35] [36,37] (see table S5 in Supplement appendix
for more detail)
TB Reactivation rate HIV/TB
co-infected
0 · 0340 [38-40] 0 · 02 [41]
MDR-TB related interventions DST performed 0 · 2 Assumption 0 · 5 Assumption
MDR- loss to follow up rate
in HIV negative cases
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for each parameter. In Indonesia, the sequential impact
of implementing several interventions that target the
public and private sector together was also considered.
In Kazakhstan, the sequential impact of implementing
several interventions that first strengthen the general
health system, and then improve the diagnosis and treat-
ment of MDR-TB was considered.
Ethics statement
This study used a hypothetical simulation model based
on previously published data, so research ethics commit-
tee approval was not required.
Availability of supporting data
All supporting data used in models are provided in the
main text and in accompanying supplementary files.
Results
Impact of interventions to improve diagnosis and
treatment of TB in the public and/or private sectors in a
low MDR/low HIV setting. Indonesia case study.
As shown in Table 2, under baseline conditions (no specific
intervention) almost two-thirds of active TB cases are pre-
dicted to die, and cure rates are very low. This reflects the
assumed problems affecting all stages of the patients’
trajectory in this baseline scenario, so that very few pa-
tients are diagnosed and treated correctly. As a result
the number of secondary cases exceeds the reactivated
primary cases – implying a net increase in incidence
over time under this scenario. The impact of interven-
tions that affect single parameters without changing
other parameters, is predicted to be quite modest, as
seen in Table 3. Interventions to improve diagnosis in
the private and public sectors are predicted to result in
the greatest reduction of deaths and secondary cases,
while interventions to improve treatment in either sec-
tor will result in greatest improvement in cures but
with less effect on deaths. Enhancing diagnosis will re-
sult in the greatest increase in health system costs,
reflecting the costs of putting more people on treat-
ment. Improvements in the diagnosis and treatment of
MDR-TB, with greater performance of drug sensitivity
testing and reduced default from treatment are pre-
dicted to have the least impact. This reflects that in
the base case analysis, most patients are not diagnosed
with TB at all, thus reducing substantially any possible
benefit of improved diagnosis and treatment of MDR-
TB (which requires that TB is first diagnosed). The
sensitivity analysis showing the impact of changing
each key parameter by an absolute value of 25% is
shown in Additional file 1: Table S6.
As shown in Figure 1, without any specific interven-
tions, more than 60% of patients are lost to follow-upwhen the public or private provider orders an incorrect
test, and another 25% are lost to follow-up prior to being
diagnosed correctly. Of those diagnosed correctly, most
are then placed on incorrect treatment; as a result less
than 10% start on correct treatment. In Indonesia, where
large numbers of TB patients access private providers,
improvements only in the public sector will produce
some benefits, but the greatest gains will be realized with
a combined approach of interventions in both public
and private sectors.
When the sequential addition of interventions in the
public and private sector was assessed, improved diagno-
sis in all sectors would substantially reduce deaths and
secondary cases, while improved treatment would cause
further important reductions in these two outcomes
(Table 4). A final reduction to near zero deaths and sec-
ondary cases would be achieved by eliminating all patients
lost to follow-up prior to the initiation of treatment.
Impact of interventions to improve diagnosis and
treatment of TB in a high MDR-TB or high HIV-TB setting.
Kazakhstan and Mozambique case studies.
In Kazakhstan, using the pre-intervention scenario as-
sumptions, a high death rate, low cure rate, and high
number of secondary cases are predicted. As with
Indonesia, interventions that change individual parame-
ters one at a time will have modest effects (Additional
file 1: Table S7). As summarized in Table 5, improved
initial diagnosis and improved treatment of DS-TB (with
first line drugs) are predicted to have the greatest impact
on mortality, the number of secondary cases, and num-
ber of cases that are cured. The least impact on these
three outcomes would result from isolated improve-
ments in diagnosis of MDR-TB (increasing drug suscep-
tibility testing from 20% to 50% of all DR cases), or
improving MDR treatment (reducing loss to follow up
from 22% to 11%), without any other programmatic
changes.
This finding was explored further in sensitivity analysis
summarized in Table 6. If the diagnosis and treatment of
DS-TB were first improved - with 100% diagnosis and
treatment and eliminating all patients lost to follow-up,
but without changes in the MDR-TB program, the num-
ber of deaths from TB and secondary cases would fall by
almost 70%, while the overall cure rate would increase
from 4% to 75%. If the DR-TB program was also im-
proved – by increasing DST coverage to 100%, and in-
creasing treatment so that 100% received standard
MDR-TB therapy, the overall cure rate would improve
from 75% to 79%. If the MDR-TB regimen included new
TB drugs that resulted in cure rates for MDR-TB equiva-
lent to the cure rates now achieved for fully susceptible
TB, this would result in an 8% further reduction in mor-
tality, and an increase in overall cure rate to 84%.
Table 2 Total projected TB related outcomes per 1,000 general population, in Indonesia over 20 years




Total projected outcomes related to the primary cases










Baseline - - - 19 · 27 12 · 52 0 · 97 28 · 87 $2,641 · 47




Test (in public sector)
60% 35% 19 · 27 11 · 90 1 · 24 27 · 38 $3,302 · 55
Diagnostic Delay2
(in public sector)
8% 0 · 5% 19 · 27 12 · 48 0 · 98 28 · 71 $2,670 · 63
Loss to follow up during
Diagnosis (in public sector)














62% 36% 19 · 27 11 · 75 1 · 33 27 · 04 $3,455 · 53
Diagnostic Delay2 (in private
sector)
11% 0 · 7% 19 · 27 12 · 46 0 · 98 28 · 63 $2,685 · 49
Loss to follow up during
Diagnosis (in private sector)
25% 14% 19 · 27 12 · 35 1 · 05 28 · 46 $2,823 · 16
Incorrect Treatment
(in private sector)
77% 13% 19 · 27 11 · 97 2 · 48 27 · 79 $2,647 · 19
HIV/ ART therapy
programmes
HIV (+) Death 12% 10% 19 · 27 12 · 52 0 · 97 28 · 87 $2,641 · 47
HIV (+) Relapse 16% 1% 19 · 27 12 · 52 0 · 97 28 · 87 $2,641 · 47
HIV (+) Reactivation 3 · 4% 2% 19 · 26 12 · 52 0 · 96 28 · 86 $2,640 · 66
MDR-TB related
interventions
DST performed 20% 50% 19 · 27 12 · 52 0 · 97 28 · 87 $2,693 · 77
Loss to follow up during MDR
Treatment
22% 11% 19 · 27 12 · 52 0 · 97 28 · 87 $2,642 · 53
Notes: 1See Table 1 for more detail; 2Delay =% with 1 year delay; 3Primary cases are those which would arise from reactivation of pre-existing latent TB infection, or progression from newly acquired infection, but do
NOT include cases arising from transmission from the primary cases.














Table 3 Changes in projected TB related outcomes relative to baseline of no intervention, per 1,000 general population, in Indonesia over 20 years
Intervention Specific parameter changed1 Change in outcomes related to primary active cases and ranking of impact3
Parameter Pre-intervention Post-intervention Death during diagnosis
and treatment phase



















Baseline - - - 12 · 52 - 0 · 97 - 28 · 87 - $2,641 · 47 -
Community
Education





60% 35% −0 · 62 2 0 · 27 4 −1 · 49 2 661 · 09 14
Diagnostic Delay2 (in public
sector)
8% 0 · 5% −0 · 04 10 0 · 01 10 −0 · 16 10 29 · 16 7
Loss to follow up during
Diagnosis (in public sector)
25% 14% −0 · 15 6 0 · 07 6 −0 · 36 6 159 · 37 12
DOTS Expansion
for Treatment
Incorrect Treatment (in public
sector)
79% 13% −0 · 50 4 1 · 36 2 −0 · 98 4 5 · 15 5
Non specific NTP
Strengthening
Access Government Facility 43% 73% −0 · 10 8 0 · 02 7 −0 · 25 8 123 · 40 11
Private Sector
interventions
Incorrect Diagnostic test (in
private sector)
62% 36% −0 · 77 1 0 · 37 3 −1 · 84 1 814 · 07 15
Diagnostic Delay2 (in private
sector)
11% 0 · 7% −0 · 07 9 0 · 02 7 −0 · 24 9 44 · 02 8
Loss to follow up during
Diagnosis (private sector)
25% 14% −0 · 17 5 0 · 08 5 −0 · 41 5 181 · 69 13
Incorrect Treatment (in
private sector)
77% 13% −0 · 56 3 1 · 51 1 −1 · 08 3 5 · 72 6
HIV/ ART therapy
programmes
HIV/TB Death rate 12% 10% 0 · 00 11 0 · 00 11 0 · 00 13 0 · 00 2
HIV/TB Relapse rate 16% 1% 0 · 00 11 0 · 00 11 0 · 00 13 0 · 00 2
HIV/TB Reactivation rate 3 · 4% 2% 0 · 00 11 0 · 00 11 −0 · 01 11 −0 · 81 1
MDR-TB related
interventions
DST performed 20% 50% 0 · 00 11 0 · 00 11 −0 · 01 11 52 · 31 9
Loss to follow up during
MDR Treatment
22% 11% 0 · 00 11 0 · 00 11 0 · 00 13 1 · 07 4
Notes: 1See Table 1 for more detail; 2Delay =% with 1 year delay; 3Rank of Impact ranks the projected impact of each intervention on each outcome, relative to the baseline of no intervention.














NO INTERVENTION PUBLIC SECTOR ONLY PUBLIC AND PRIVATE SECTOR
Data table to support figures (probability of each event occurring)
Pre-Intervention Post-Intervention
Public Sector Private Sector Public Sector Private Sector 
Incorrect diagnostic test ordered by health 
professional 60.3% 62.2% 35.1% 36.2%
Loss to follow up during diagnostic work up 25.4% 25.4% 14.0% 14.0%
Diagnostic delay of 1 year 8.1% 11.0% 0.5% 0.7%
Started on incorrect regimen 79.1% 77.1% 12.9% 12.6%
Figure 1 Probability of intermediate outcomes if interventions are applied in public and or private sectors and achieve improvements
in diagnosis and treatment as summarized below, in drug sensitive TB patients, in Indonesia.
Oxlade et al. BMC Public Health  (2015) 15:141 Page 8 of 14When these analyses were repeated using epidemio-
logic parameters from Mozambique (Tables 7 and 8),
without any interventions, the number of deaths are
much higher. Increasing ART treatment of HIV co-
infected TB patients would result in the greatest re-
duction in mortality and secondary TB cases, plusTable 4 Projected outcomes over 20 years with progressive a
private sectors for TB care in Indonesia (per 1000 persons fro








Baseline 19 · 27 11 · 01 1 ·
Eliminate patient delay
in seeking care
















19 · 27 3 · 67 0 ·
Above & Eliminate
loss to follow up
prior to starting
treatment
19 · 27 0 0 ·
1Primary cases are those which would arise from reactivation of pre-existing latent
cases arising from transmission from the primary cases.produce net savings to the health system. This is the
only intervention that results in a reduction of the
number of primary TB cases, as it actually prevents TB
cases. Interventions that enhance the laboratory net-
work to improve diagnosis would have the next great-
est impact.ddition of interventions that improve the public and
m general population)










51 0 · 97 28 · 87 $2,641 · 47
57 1 · 01 28 · 21 $2,751 · 94
67 1 · 06 27 · 88 $2,916 · 34
31 2 · 75 18 · 64 $6,809 · 05
44 2 · 84 17 · 40 $7,013 · 83
72 12 · 95 9 · 59 $7,052 · 06
96 17 · 35 1 · 39 $9,295 · 09
TB infection, or progression from newly acquired infection, but do NOT include
Table 5 Changes in projected TB related outcomes relative to baseline of no intervention per 1,000 general population, in Kazakhstan over 20 years
General
intervention
Specific parameter changed1 Projected changes in outcomes related to the primary active cases and Ranking of
impact3

























Baseline outcomes - - - 10 · 05 0 · 62 22 · 99 $5,238 · 87
Community
Education
Patient delay2 11% 6% −0 · 14 3 0 · 01 5 −0 · 26 5 111 · 34 3
DOTS expansion for
diagnosis
Incorrect Diagnostic Test 60% 35% −1 · 88 1 0 · 40 2 −2 · 47 1 2947 · 81 9
Diagnostic Delay2 8% 0 · 5% −0 · 11 4 0 · 02 4 −0 · 27 4 132 · 69 4
Loss to follow up during Diagnosis 25% 14% −0 · 45 2 0 · 10 3 −0 · 60 3 710 · 63 8
DOTS Expansion for
Treatment




Access Government Facility 94 · 5% 97 · 5% −0 · 09 5 0 · 02 4 −0 · 12 6 164 · 65 5
HIV/ ART therapy
programmes
HIV/TB Death rate 12% 10% 0 · 00 6 0 · 00 6 0 · 00 8 0 · 00 2
HIV/TB Relapse rate 16% 1% 0 · 00 6 0 · 00 6 0 · 00 8 0 · 00 2
HIV/TB Reactivation rate 3 · 4% 2% 0 · 00 7 0 · 01 5 0 · 05 9 −142 · 43 1
MDR-TB related
interventions
DST performed 20% 50% 0 · 00 6 0 · 02 4 −0 · 03 7 232 · 19 6
Loss to follow up during MDR
Treatment
22% 11% 0 · 00 6 0 · 00 6 0 · 00 8 10 · 11 3
Notes: 1See Table 1 for more detail; 2Delay =% with 1 year delay; 3Rank of Impact ranks the projected impact of each intervention on each outcome, relative to the baseline of no intervention.














Table 6 Projected outcomes over 20 years with progressive addition of interventions that improve general TB services


















Baseline 15 · 28 10 · 05 0 · 62 22 · 99 $5,238 · 87
General Health
System Interventions
Improved diagnosis to detect
100% of TB cases in public
sector (DS and MDR)
15 · 28 7 · 67 1 · 57 17 · 07 $12,292 · 55
Above & improved treatment
to achieve 100% cure for DS
in public sector
15 · 28 4 · 96 8 · 60 12 · 22 $12,354 · 14
Above & reduced loss to follow
up in public sector
15 · 28 2 · 70 11 · 53 7 · 23 $16,351 · 62
MDR-TB related
interventions
Above & Improve DST coverage
to 100%
15 · 28 2 · 59 11 · 72 6 · 96 $18,441 · 46
Above & Improved treatment
coverage so that all MDR cases
diagnosed get standard MDR
therapy
15 · 28 2 · 07 12 · 61 5 · 66 $27,327 · 96
Above & New MDR drugs so
treatment outcomes are as
good as drug sensitive TB cases
15 · 28 1 · 85 13 · 11 5 · 41 $28,513 · 34
1Primary cases are those which would arise from reactivation of pre-existing latent TB infection, or progression from newly acquired infection, but do NOT include
cases arising from transmission from the primary cases.
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In our study, the greatest gains in reducing TB deaths
and secondary cases are expected to come from inter-
ventions that reduce the reactivation rate to disease
(ie. ART for HIV co-infected patients), or affect all pa-
tients with TB disease early in their trajectory, by im-
proving their diagnosis. Further gains are made if
treatment is also improved. In settings with a promin-
ent private sector such as Indonesia, these achieve-
ments will be even greater if interventions are directed
to both the public and private sectors. Even in settings
with high levels of MDR-TB, we predict that interven-
tions that improve diagnosis of all TB patients plus
treat DS-TB cases correctly will have greater overall
impact. The finding that the foundation for successful
scale up of interventions is the strengthening of initial
diagnosis and appropriate timely treatment of persons
with TB supports current WHO recommendations for
health system strengthening, TB prevention, diagnosis
and treatment programs [42].
In the base case scenario, TB related mortality rates
are projected to be very high in all settings, reflecting
very low overall rates of successful diagnosis and treat-
ment. In the model, TB cases that are undiagnosed die
at rates consistent with those reported for smear positive
cases in the pre-antibiotic era (approximately 33% per
year [43]). In recent national prevalence surveys thenumber of TB cases that are undiagnosed has been
found to be remarkably high. For example, in Nigeria,
the case detection rate is now estimated to be only 16%,
and TB mortality was found to be 400% higher than pre-
viously estimated rates [3]. Indonesia has also recently
completed a prevalence survey but results are not yet
published. In the 2014 Global TB report however, WHO
suggests that results will lead to revisions of previously
published global TB estimates [3].
The interventions included in this analysis are those
most commonly introduced for TB prevention, diagnosis
and treatment in LMIC as part of Stop TB Global plans,
and were restricted to those for which there is published
evidence of their potential impact. Several interventions
were initially considered but ultimately excluded for the
following reasons: 1) There was insufficient published
data regarding their effect, 2) They had an overarching
effect that influenced multiple elements within the con-
ceptual framework so a precise effect within the model
could not be assumed, or 3) published pre-intervention
estimates were already excellent. The independent ef-
fects of each intervention can be very difficult to assess
in field studies because in most countries multiple inter-
ventions have been applied simultaneously. Other mod-
eling studies have considered the relative impact of
different interventions [44-46], but not the impact of
multiple interventions, nor multiple sectors. In this
Table 7 Total projected TB related outcomes per 1,000 population, in Mozambique over 20 years
Interventions Specific parameter change1 Primary active cases
arising in cohort over
20 years3
Total projected outcomes related to the primary cases









Baseline - - - 69.82 47.34 2.40 106.05 $2,818.01
Community Education Patient delay2 11% 6% 69.82 45.97 2.51 104.24 $2,955.56
DOTS expansion for diagnosis Incorrect Diagnostic Test 60% 35% 69.82 39.57 3.92 94.82 $4,075.36
Diagnostic Delay2 8% 0.5% 69.82 46.29 2.54 104.44 $2,942.14
Loss to follow up during
diagnosis
25% 14% 69.82 45.47 2.76 103.35 $3,121.12
DOTS Expansion for Treatment Incorrect Treatment 79% 13% 69.82 47.34 10.00 99.21 $2,920.66
Non specific DOTS Expansion
(NTP Strengthening)
Access Government Facility 94.5% 97.5% 69.82 46.96 2.47 105.50 $2,906.57
HIV/ ART therapy programmes HIV/TB Death rate 12% 10% 69.82 47.34 2.45 106.05 $2,818.01
HIV/TB Relapse rate 16% 1% 69.82 47.34 2.70 105.93 $2,818.01
HIV/TB Reactivation rate 3.4% 2% 57.11 39.55 2.01 86.58 $2,326.66
MDR-TB related interventions DST performed 20% 50% 69.82 47.34 2.41 106.02 $2,986.38
Loss to follow up during
MDR Treatment
22% 11% 69.82 47.34 2.40 106.05 $2,819.07
Notes: 1See Table 1 for more detail; 2Delay =% with 1 year delay; 3Primary cases are those which would arise from reactivation of pre-existing latent TB infection, or progression from newly acquired infection, but do
NOT include cases arising from transmission from the primary cases.














Table 8 Changes in projected TB related outcomes per 1,000 population, in Mozambique over 20 years
General intervention Specific parameter changed1 Projected changes in outcomes related to the primary active cases









Baseline outcomes - - - 47.34 2.40 106.05 $2,818.01





60% 35% −7.77 1.52 −11.23 1257.35
Diagnostic Delay2 8% 0.5% −1.05 0.14 −1.61 124.13
Drop out during
Diagnosis
25% 14% −1.87 0.37 −2.71 303.11
DOTS Expansion for
Treatment






94.5% 97.5% −0.38 0.08 −0.56 88.57
HIV/ ART therapy
programmes
HIV/TB Death rate 12% 10% 0.00 0.05 0.00 0.00
HIV/TB Relapse rate 16% 1% 0.00 0.30 −0.12 0.00
HIV/TB Reactivation
rate
3.4% 2% −7.79 −0.39 −19.47 −491.35
MDR-TB related
interventions
DST performed 20% 50% 0.00 0.02 −0.03 168.37
Loss to follow up
during MDR
Treatment
22% 11% 0.00 0.00 0.00 1.06
Notes: 1See Table 1 for more detail; 2Delay = % with 1 year delay.
(Change in estimate shown represents change relative to baseline for a change in only one parameter and all others remain at pre-intervention values).
Oxlade et al. BMC Public Health  (2015) 15:141 Page 12 of 14study we compared the relative impact of interventions
separately, in combination, and across multiple sectors -
which is more realistic. In addition, our study included
health system costs which were not considered in de-
tail in other studies which modeled epidemiologic out-
comes [44-46].
Nevertheless this study has several limitations. First,
although the number of secondary cases that originate
from active cases were predicted in our model, these
cases do not influence the annual risk of infection in
subsequent years. Thus the population level impact of
interventions was not directly evaluated and our findings
are likely conservative. This limitation has implications
particularly for DR-TB interventions, because preventing
transmission (through prompt diagnosis and effective
treatment) is an important goal. In all 3 countries mod-
eled, interventions directed at improved diagnosis or
treatment of MDR-TB were projected to have less im-
pact than interventions to prevent primary cases, or to
enhance early diagnosis of all TB cases. This is because
patients with MDR-TB must first be diagnosed with TB,
in order to have DST performed. Hence performing
DST on a small fraction of all cases (when all the
remaining cases have not been diagnosed at all) will in-
evitably have less impact than if diagnosis of all cases
is improved first, since MDR-TB cases can only bediagnosed with DST. We also found that improving
treatment of DS-TB cases would have more impact
than improving treatment of MDR-TB, even when we
assumed very high cure rates – similar to recently re-
ported cure rates with new shorter MDR regimens
[47]. This reflects the fact that even in a high MDR
prevalence setting the majority of cases (>70%) are DS-
TB. This is also combined with the fact that DS-TB
regimens have a greater treatment success rate (aver-
aging >90% [48]) than do MDR-TB regimens (aver-
aging 55-60% [36]). As detection of DS-TB continues
to improve, the impact of MDR-TB interventions will
also have the potential to improve.
Second, the magnitude of the effect sizes for some of
the interventions were large. Studies that documented
the effect of interventions were identified through an ex-
tensive review of the literature, but some of these im-
provements were reported from single studies, some of
which involved small study populations, or had short pe-
riods of follow-up. It is unclear if these improvements
could be obtained or sustained when applied on a na-
tional scale. Finally, we could not perform a comprehen-
sive cost effectiveness study, because the costs associated
with interventions were not available from the studies that
reported outcomes resulting from these interventions.
This emphasizes the need for systematic collection and
Oxlade et al. BMC Public Health  (2015) 15:141 Page 13 of 14reporting of cost data in future studies of similar
interventions.
In the post 2015 era there has been a call to accelerate
progress by building on national and global efforts that
have already had an impact on TB indicators [42,49].
Our sensitivity analysis on TB mortality (Table 4) con-
sidered in detail the substantial effort that will be re-
quired to meet the WHO goal of zero TB deaths. Scale
up and strengthening of interventions like those in-
cluded in our analysis should help to accelerate progress
toward these ambitious goals, however the rate at which
gains can be made will depend on the both the ongoing
political and financial commitment to combat TB at
both a global and national level.
Conclusion
In all settings, the greatest benefit will come from inter-
ventions that reduce reactivation to disease, or those
that increase early diagnosis and improve treatment for
DS-TB as well as DR-TB. Once this has been achieved
more specific interventions, such as those targeting HIV,
drug resistance or the private sector can be integrated to
increase impact. The findings of this study may provide
useful information to guide selection of TB interventions
in different settings, particularly as programs begin to
scale-up interventions in the private sector and financial
schemes are developed and improved to address univer-
sal health coverage.
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